The first drug shown to slow Alzheimer’s disease hit the US market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage. Doctors also expect some patients will hesitate to take Leqembi due to its limited…
The first drug shown to slow Alzheimer’s hit the U.S. market over a year ago, but sales have lagged and diagnosis and treatment remain complicated. Major hospital systems have taken
New data from TRAILBLAZER-ALZ 2 show robust amyloid clearance with donanemab in APOE4 carriers and noncarriers, mitigating the risk of disease progression and dependency.
Next Goals for Immunotherapy: Make It Safer, Less of a Hassle alzforum.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from alzforum.org Daily Mail and Mail on Sunday newspapers.
Broad participation at this year's congress highlights Prothena's leadership in advancing next generation treatments for Alzheimer's and Parkinson's disease Oral presentation on PRX012, Prothena's